NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: The Scott Partnership
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Quotient Clinical Demonstrates Effective Drug Product Optimisation with RapidFACT Platform - Quotient Clinical, a strategic business unit of leading drug development services provider Quotient Bioresearch (
Quotient Clinical Demonstrates Effective Drug Product Optimisation with RapidFACT Platform

 

NewswireToday - /newswire/ - Cambridgeshire, United Kingdom, 2009/10/27 - Quotient Clinical, a strategic business unit of leading drug development services provider Quotient Bioresearch ("Quotient").

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

today announces the availability of a new white paper demonstrating the advanced capabilities of the novel RapidFACT approach: an integrated formulation development, manufacture and clinical testing service. RapidFACT can be used to optimise drug products with significantly shorter timelines and reduced associated expenditure compared to traditional approaches. The new white paper, entitled "RapidFACT - a New Paradigm for the Effective Optimisation of Oral Dosage Forms", is available to download free-of-charge.

A conventional drug product optimisation process involves iterative rounds of screening multiple formulation prototypes in preclinical species to identify a limited number of "lead" systems to progress into human clinical PK studies. This process is time consuming and expensive, costing over £1m and taking over 18 months. Quotient's RapidFACT service can reduce this timeline by up to two thirds and significantly reduces associated costs.

RapidFACT exploits Quotient's Translational Pharmaceutics platform which integrates formulation development, GMP drug product manufacture and clinical testing facilities to allow products to be manufactured and investigated in a clinical study in timeframes as short as 24 hours. Candidate formulations can be rapidly screened, selected and validated on the basis of human clinical data. This significantly improves the precision by which an optimal drug product that matches the desired target product profile can be identified.

Mark Egerton, Chief Executive Officer of Quotient Clinical comments, "The increasingly competitive nature of the pharmaceutical industry inevitably means that any approach which saves time and money and increases the chances of development success, is welcomed by our clients. We have now completed RapidFACT programs for a number of our pharma and biotech clients and the results have been very pleasing. We have clearly demonstrated our ability to accelerate early development".

To find out more about RapidFACT or to obtain a copy of the new white paper please email or call Quotient Clinical on +44 (0)115 9749000 for further information.

For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. T: +44 1477 539 539 F: +44 1477 539 540 E: quotient[.]scottpr.com.

About Quotient Clinical
Quotient Clinical is a strategic business unit of Quotient Bioresearch. It was formed in May 2009 following the acquisitions of two companies, Charles River Laboratories' Edinburgh clinical research facility in May 2009 (formerly Inveresk Clinical Research) and Pharmaceutical Profiles in December 2008. Quotient Clinical specialises in early clinical drug development, and offers a unique streamlined process to reduce the time from First-in-Man studies through to proof of concept, integrating flexible drug product manufacture into clinical trials. With an existing strong customer base in the United States, Europe and Japan, the principal focus of Quotient Clinical is to provide a unique and comprehensive range of early development services to a broad range of pharmaceutical and biotechnology customers.

About Quotient Bioresearch
Quotient is a leading provider of drug development services with a focus on early-stage drug development services. The Company offers a unique range of drug development services through its three principal operating units - Quotient Chemistry & Metabolism, Quotient Bioanalytical Sciences and Quotient Clinical. Quotient has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Quotient Bioresearch (quotientbioresearch.com) is part of Quotient Bioscience Group, which comprises Quotient Bioresearch, HFL Sport Science and Quotient Biodiagnostics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services / Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Quotient Clinical Demonstrates Effective Drug Product Optimisation with RapidFACT Platform

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Sarah Evans 
+44(0)14 7753 9539 clinical[.]quotientbioresearch.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Medical Services / Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Medical Services / Equipment Most Recent Related Newswires:

Bruker Launches IconIR Nanoscale IR Spectroscopy Platform
Artificial Intelligence to Boost the Global Wound Care Market by 2026 with Minimal Intervention Solutions Finds Frost & Sullivan
Imec Signs Licensing Agreement with miDiagnostics to Commercialize its Patented Technology for Fast and Reliable COVID-19 Diagnosis
Withings Announces the FDA Clearance of ScanWatch its Most Medically Advanced Hybrid Smartwatch
Bruker Launches the Q4 POLO - Compact Spark-OES Metals Analyzer
Respiratory Health Management Market to Expedite Digital, Smart, and Portable Solutions Says Frost & Sullivan
Bruker Joins PANACEA Network to Broaden Access to NMR for European Chemistry Community
High-end Global Computed Tomography Purchases to Propel the High-end CT Segment Revenue Finds Frost & Sullivan
KRAIBURG TPE Introduces Ergonomically Designed Healthcare Equipment
Fujifilm Lauded by Frost & Sullivan for Disrupting the Operating Room Space with its Systems Integration Solution
BASF’s Irgastab® Enables LOTTE Chemical to Deliver High-clarity Medical Polypropylene for Syringes Used in COVID-19 Vaccinations
Withings and One Drop Partner to Bring Best-in-class Medical Devices to Multi-condition Employer Program
BIOTRONIK Applauded by Frost & Sullivan for its Disruptive Implantable Cardiac Monitoring Device, BIOMONITOR IIIm
Sensor Technologies for Pressure Injury Prevention Improve Outcomes and Operational Efficiency for Hospitals Finds Frost & Sullivan
New Bruker NMR Life Science Research Solutions Enable Functional Structural and Cellular Biology Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)